{"name":"Septerna","slug":"septerna","ticker":"SEPN","exchange":"NASDAQ","domain":"septerna.com","description":"Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as G","hq":"South San Francisco, CA","founded":0,"employees":"130","ceo":"Abbas Hussain","sector":"GI / Metabolic","stockPrice":26.7,"stockChange":1.95,"stockChangePercent":7.88,"marketCap":"$1.2B","metrics":{"revenue":72255000,"revenueGrowth":12011,"grossMargin":100,"rdSpend":97584000,"netIncome":-48879000,"cash":347400992,"dividendYield":0,"peRatio":-14.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"SEP-229 patent cliff ($0.0B at risk)","drug":"SEP-229","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SEP-479","genericName":"SEP-479","slug":"sep-479","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SEP-479","genericName":"SEP-479","slug":"sep-479","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Septerna Announces FDA Fast Track Designation for SEP-229","summary":"Septerna announced that the FDA has granted Fast Track designation to SEP-229 for the treatment of a rare gastrointestinal disorder.","drugName":"SEP-229","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Septerna Reports Third Quarter 2023 Financial Results","summary":"Septerna reported its third-quarter 2023 financial results, with a net loss of $23.4 million and a cash balance of $143.8 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-11","type":"earnings","source":"simplywall.st","summary":"Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative - simplywall.st","headline":"Septerna (SEPN) Q4 Loss Despite Revenue Surge Reinforces Bearish Profitability Narrative","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-10","type":"trial","source":"simplywall.st","summary":"Assessing Septerna (SEPN) Valuation After Earnings Progress And Positive SEP-631 Phase 1 Results - simplywall.st","headline":"Assessing Septerna (SEPN) Valuation After Earnings Progress And Positive SEP-631 Phase 1 Results","sentiment":"positive"},{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-05","type":"pipeline","source":"simplywall.st","summary":"We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn - simplywall.st","headline":"We're Not Worried About Septerna's (NASDAQ:SEPN) Cash Burn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9EVnQwM1Budnk5Um1vQkJtelpuVXZ3SVdkRk9yYl91S2lpNkZqSDNjbzVKS1hmOFJ6NEh0c2tHTmZhV1JsQ09JZV9GWGRmVWJ3b3pzX0U4OTNCT1JDZVlQTUZRNS1WSzdZ?oc=5","date":"2025-07-10","type":"regulatory","source":"MarketBeat","summary":"Septerna (SEPN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Septerna (SEPN) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPbHd4cjJoOUszVFMxdGczQU5ZRm1adWpsUXZZMWcxUUI0anFTSy0zTkhoWnFybkxRamtYaE5HOWxXWlJwNVBDVU14SVBZYXNZOFp1OGozVTNWTk5vcVRrMEVaLWsteVFrYXZrVWQ4ZTdUUjVJVUNFaEwtZ1gydXJhRWNzZThIWlRScmVDNndUejJGMmxVamJCQmRBSjI?oc=5","date":"2025-05-16","type":"pipeline","source":"Seeking Alpha","summary":"Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist - Seeking Alpha","headline":"Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQQzBSaDlOWUk2bV9QbWVFMjRaaHlYeFkwdjJHX1dvRU9qazVDRnhqNkdJLUFHNTdkNVVtcmhWOURaMjFEZHJ4TC00QkN3bXBfNkhnclEzMDNvakM5bjk1ZGtYRW55dFRhM3EzVm9XQS1ianVra3k0Q2t2X2J0eVF0NHNMemZfZFcyb0tF?oc=5","date":"2025-05-15","type":"deal","source":"Yahoo Finance","summary":"ETFs to Capitalize on the Novo Nordisk-Septerna Deal - Yahoo Finance","headline":"ETFs to Capitalize on the Novo Nordisk-Septerna Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNRlBCRjlSOVJhYmVscGlCdUtiR014c2pUY2dNRmFpdmxmbHFxTkI0eHEwRmlac2F0X3VZd0lDVWwxbW8xaTRYYjF6UGVGYmdzNjlhTjd0bTBHdFBkWDFpQjhXdFFiV0dXWXhnQndrSmNKdjZRY3hvM2g4Z3JpSEZfS29RV0lZN3BXckNMTnZ5Tk5BNFdlZ20xOWFYZlZ2eWRMNms0SllWWDBmcG1DTnFpSXVDcWpXNTExUTZEcGVPdmZWZTZodlVIdnVoOFVKMDZuTWU3ZEZkT1Y3Zw?oc=5","date":"2025-05-14","type":"deal","source":"Reuters","summary":"Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters","headline":"Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOcDQ5VE1Uemxpalhlc1hBWjJtZzNUOW5PQVdJVXY2c1pHaGs5ZXJnVkttVGRSMHRaQWZva1BmNlhrN2QtZHcyRnlNbHBGNzdnMFU4VGVNTjdXSHM1VGFaV0ZBaFU3RGNLZ2pNdTZldkpjRDU2QjJWTWo5dWxXelhCR21Zdlk1SHBfR2VfTHAtdFlQMExDQmhkeDB2anRxZkNTaVNhMjNSdmw0UUo4d2FV?oc=5","date":"2025-02-18","type":"pipeline","source":"Fierce Biotech","summary":"Septerna drops lead asset over bilirubin side effects 4 months after going public - Fierce Biotech","headline":"Septerna drops lead asset over bilirubin side effects 4 months after going public","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQZ3I2RHdzSWZIS1BCYzZ2WEl2RkdReUtHRmNLUHZoMm5JR0lSNFJUenRZbllOdUFINHlnRVZndGlReGdaclBQaktOajFpSjBJRGlwZkgtNS1IcS0zZXJjMTBGZFk4MjVBNXZ0S1UzbVl5aENuczNiYzRCMUV4MVBNdmJpUFlZYWNfS2xGUW43NTNnN1hTSW9vXzJjVk5hQlQwVFdnRFFzWQ?oc=5","date":"2025-02-18","type":"pipeline","source":"bioworld.com","summary":"Septerna pulls lead hypoparathyroidism drug on bilirubin levels - bioworld.com","headline":"Septerna pulls lead hypoparathyroidism drug on bilirubin levels","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQaE95MGpTSzVmVUtXVVFCaWNWUHdMcG81OTVTZGhSSklHQ1R3RDh3WU9pX3Z0VC1OTm83M1NpaEoxS25DakNqSlZWQjZkX1o5SVF0bENkY1hzVUdwZWlPU25QLUJILUFMZDdqWGh4WEp1d2hReFE0ZW5PLXNtRDc1YQ?oc=5","date":"2024-10-31","type":"pipeline","source":"pharmaphorum","summary":"Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum","headline":"Nasdaq debutante Septerna swells its IPO to $331m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxON3lHbEpDWV9fcEF1Rnc3d3lHeXRjWXdfMjFPbFdHWWZoX21LSjRsa2x4VjFYQ1g1dmZ4cklidDNTcThGaWlpdHptS2libVVNWk5jLVZzdEVhbDdOanBmTTFnTVplaEg1aEN3UjhyZC10M3EwTHNDUFZoclY2Mk9XNQ?oc=5","date":"2024-10-26","type":"pipeline","source":"MarketBeat","summary":"Top Septerna (SEPN) Competitors 2026 - MarketBeat","headline":"Top Septerna (SEPN) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"SEP-229","drugSlug":"generic-name-not-available","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Janssen Pharmaceuticals","AstraZeneca"],"therapeuticFocus":["Gastrointestinal Diseases","Metabolic Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":45951000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":45951000,"period":"2025-12-31"},{"value":1075000,"period":"2024-12-31"},{"value":1075000,"period":"2024-12-31"},{"value":151000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":97584000,"rdSpendHistory":[{"period":"2025-12-31","value":97584000},{"period":"2024-12-31","value":65337000},{"period":"2023-12-31","value":35979000},{"period":"2022-12-31","value":22044000}],"sgaSpend":29164000,"operatingIncome":-80797000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-80797000},{"period":"2024-12-31","value":-80823000},{"period":"2023-12-31","value":-45550000},{"period":"2022-12-31","value":-27967000}],"netIncome":-48879000,"netIncomeHistory":[{"period":"2025-12-31","value":-48879000},{"period":"2024-12-31","value":-71798000},{"period":"2023-12-31","value":4180000},{"period":"2022-12-31","value":-27676000}],"eps":-7.26,"epsHistory":[{"period":"2024-12-31","value":-7.26},{"period":"2023-12-31","value":0.029083},{"period":"2022-12-31","value":-1.419591}],"cash":120722000,"cashHistory":[{"period":"2025-12-31","value":120722000},{"period":"2024-12-31","value":238196000},{"period":"2023-12-31","value":88483000},{"period":"2022-12-31","value":30607000}],"totalAssets":596187000,"totalLiabilities":214261000,"totalDebt":23625000,"equity":381926000,"operatingCashflow":110189000,"operatingCashflowHistory":[{"period":"2025-12-31","value":110189000},{"period":"2024-12-31","value":-67470000},{"period":"2023-12-31","value":-38723000},{"period":"2022-12-31","value":-23303000}],"capex":-518000,"capexHistory":[{"period":"2025-12-31","value":-518000},{"period":"2024-12-31","value":-2103000},{"period":"2023-12-31","value":-2878000},{"period":"2022-12-31","value":-1289000}],"freeCashflow":109671000,"dividendsPaid":null,"buybacks":-1000,"employees":130,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8280000,"ebit":-16023000,"ebitda":-15622000,"period":"2025-12-31","revenue":24118000,"epsBasic":-0.24,"netIncome":-10738000,"rdExpense":31861000,"epsDiluted":-0.24,"grossProfit":null,"operatingIncome":-16023000},{"sga":7117000,"ebit":-9886000,"ebitda":-9485000,"period":"2025-09-30","revenue":21495000,"epsBasic":0.18,"netIncome":8173000,"rdExpense":24264000,"epsDiluted":0.18,"grossProfit":null,"operatingIncome":-9886000},{"sga":6909000,"ebit":-28978000,"ebitda":-28573000,"period":"2025-06-30","revenue":119000,"epsBasic":-0.56,"netIncome":-24838000,"rdExpense":22188000,"epsDiluted":-0.56,"grossProfit":null,"operatingIncome":-28978000},{"sga":6858000,"ebit":-25910000,"ebitda":-25513000,"period":"2025-03-31","revenue":219000,"epsBasic":-0.49,"netIncome":-21476000,"rdExpense":19271000,"epsDiluted":-0.49,"grossProfit":null,"operatingIncome":-25910000},{"sga":5613000,"ebit":-24718000,"ebitda":-24330000,"period":"2024-12-31","revenue":212000,"epsBasic":-0.64,"netIncome":-20668000,"rdExpense":19317000,"epsDiluted":-0.64,"grossProfit":null,"operatingIncome":-24718000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":26.7,"previousClose":24.75,"fiftyTwoWeekHigh":32.63,"fiftyTwoWeekLow":8.86,"fiftyTwoWeekRange":"8.86 - 32.63","fiftyDayAverage":24.99,"twoHundredDayAverage":22.4,"beta":0,"enterpriseValue":791308416,"forwardPE":-14.9,"priceToBook":3.13,"priceToSales":16.65,"enterpriseToRevenue":10.95,"enterpriseToEbitda":-11.89,"pegRatio":0,"ebitda":-66559000,"ebitdaMargin":-92.1,"freeCashflow":24014124,"operatingCashflow":107899000,"totalDebt":23090000,"debtToEquity":6.1,"currentRatio":4.71,"returnOnAssets":-8.5,"returnOnEquity":-9.3,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":44.25,"targetHighPrice":60,"targetLowPrice":35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.1,"institutionHeldPercent":103.7,"sharesOutstanding":45075533,"floatShares":22982662,"sharesShort":2067671,"shortRatio":6.1,"shortPercentOfFloat":4.6,"epsTrailing":-0.8,"epsForward":-1.79,"revenuePerShare":1.62,"bookValue":8.52,"officers":[{"age":58,"name":"Dr. Jeffrey T. Finer M.D., Ph.D.","title":"Co-Founder, CEO & Director"},{"age":57,"name":"Ms. Elizabeth P. Bhatt M.B.A., M.S.","title":"President & COO"},{"age":53,"name":"Mr. Gilbert M. Labrucherie C.F.A., J.D.","title":"Chief Financial Officer"},{"age":81,"name":"Dr. Robert J. Lefkowitz M.D.","title":"Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board"},{"age":null,"name":"Dr. Arthur  Christopoulos BPHARM, Ph.D.","title":"Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board"},{"age":null,"name":"Dr. Patrick  Sexton Ph.D.","title":"Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board"},{"age":null,"name":"Mr. Richard  Hansen Ph.D.","title":"Vice President of Technology"},{"age":53,"name":"Mr. Mark A. Wilson J.D.","title":"Chief Legal Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://septerna.com","phone":"650 338 3533"}}